Skip to main content
. 2019 Dec 27;38(10):1006–1018. doi: 10.1200/JCO.19.00895

FIG 3.

FIG 3.

Different patterns of CSF3R-mutation variant allele frequency (VAF) changes over time with ruxolitinib. The status of the patient and cycle they reached as of data cutoff are indicated. (A) CNL-16, on study C19. (B) CNL-17, on study C16. (C) CNL-05, on study C43. (D) CNL-08, off study C19. C, cycle; CNL, chronic neutrophilic leukemia; CR, complete response; PR, partial response.